The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its ...

Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA.

Representative Jefferson Shreve (R-Indiana) recently bought shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX). In a filing disclosed on March 09th, the Representative disclosed that they had ...

The Boston-based company's new medication, called Journavx, is being placed on a tier that means it might be costlier than ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

The stock's fall snapped a four-day winning streak.

Vertex Pharmaceuticals operates in a profitable subsector and is poised for further success ...

Vertex has backed out of its in vivo gene editing collaboration with Verve Therapeuti | Vertex has backed out of its in vivo ...

Vertex announced that the United Kingdom Medicines and Healthcare products Regulatory Agency has granted approval for ALYFTREK, a once-daily ...

Vertex e-Invoicing solution enables businesses to automate accounts payable and accounts receivable transactions, streamline indirect tax reporting and reconcile VAT filings—all within a scalable, ...